Eloxx Pharmaceuticals
Clinical-stage biopharma company developing novel RNA-modulating drug candidates to treat rare and ultra rare diseases.
12 employees · est. 2013 · Watertown, United States
SCYNEXIS, Inc.
Advancing innovative solutions for severe rare diseases
49 employees · est. 2000 · Jersey City, United States
SCYNEXIS, Inc. is the older company (2013 vs 2000).
Side-by-Side Comparison
| Metric | Eloxx Pharmaceuticals | SCYNEXIS, Inc. |
|---|---|---|
| Founded | ||
| Founded | 2013 | 2000 older |
| Headquarters | ||
| Headquarters | Watertown, United States | Jersey City, United States |
| Employees | ||
| Employees | 12 | 49 |
| Industry | ||
| Industry | Not tracked yet | Biotechnology |
| Funding Stage | ||
| Funding Stage | IPO | Unknown |
| Total Funding | ||
| Total Funding | $63.29M | $319.40M |
| Funding Rounds | ||
| Funding Rounds | 11 | 10 |
| Services | ||
| Services | Development of small molecule genetic therapies, Research in ribosomal mutation correction, Treatment pipeline for rare genetic diseases | Development of AMPK activators, Creation of antifungal triterpenoids, Research and development in rare diseases, Clinical trial execution, Pharmaceutical innovation |
| Target Customers | ||
| Target Customers | Healthcare providers, Patients with rare genetic disorders, Research institutions, Biopharmaceutical investors | Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD), Individuals vulnerable to severe fungal infections, Healthcare providers focusing on rare diseases, Biotech and pharmaceutical industry partners |
| Taxonomy | ||
| Taxonomy | Biopharma, RNA-modulating Drug Candidates, Premature Stop Codon Diseases, Rare Diseases, Ultra-rare Diseases, Genetic Diseases, MRNA Half-life, Protein Synthesis, ELX-02, Cystic Fibrosis, Cystinosis, Clinical-stage Biopharmaceutical Company, Drug Development, Regulatory Approval, Waltham, MA | Rare Diseases, Severe Rare Diseases, Progressive Rare Diseases, Clinical-Stage Assets, Drug Development, Therapeutic Innovation, Unmet Medical Needs, Infectious Diseases, Fungal Diseases, Targeting Underlying Biology, Patient-Centric Solutions, Advancing Clinical Programs, Scientific Expertise, Disciplined Drug Development |
| Website | ||
| Website | eloxxpharma.com | scynexis.com |
About Eloxx Pharmaceuticals
Eloxx Pharmaceuticals is a clinical-stage biopharmaceutical company on the cutting edge of developing RNA-modulating drug candidates aimed at treating rare and ultra-rare diseases. Their motto, "Clinical-stage biopharma company developing novel RNA-modulating drug candidates to treat rare and ultra...
About SCYNEXIS, Inc.
SCYNEXIS, Inc., founded in 2000, is a biotechnology company dedicated to providing innovative solutions for patients with severe, progressive, and underserved rare diseases. Their commitment to addressing significant unmet medical needs highlights the company's potential for differentiated innovatio...
We will tell you when either one moves
BounceWatch watches Eloxx Pharmaceuticals and SCYNEXIS, Inc. for new funding, fast hiring, new executives and a change of software vendor. When one happens, we email you the same day.
Funding, hiring, leadership and stack changes at Eloxx Pharmaceuticals and SCYNEXIS, Inc. — by email.
Frequently Asked Questions
Compare Eloxx Pharmaceuticals with someone else
Start typing a company name or domain.
Related Comparisons
Compiled from the BounceWatch company index. We last looked at Eloxx Pharmaceuticals on 12 Sep 2024, and SCYNEXIS, Inc. on 9 Jun 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.
